Pre-admission anticoagulant therapy and mortality in hospitalized COVID-19 patients: A retrospective cohort study

The high risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), collectively termed venous thromboembolism (VTE), in patients with Coronavirus disease 2019 (COVID-19) is now well-established [1]. Current guidelines recommend routine use of prophylactic-dose low-molecular-weight heparin in hospitalized COVID-19 to reduce the risk of macrovascular and microvascular complications [2]. However, it is unknown whether continuing pre-admission therapeutic anticoagulation for other indications than COVID-19 is associated with favorable outcomes by mitigating hypercoagulability.